Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and Co's other long-term assets for the quarter that ended in Mar. 2026 was CHF14,629 Mil.
Eli Lilly and Co's quarterly other long-term assets
increased
from Sep. 2025 (CHF12,256 Mil) to Dec. 2025 (CHF13,508 Mil) and
increased
from Dec. 2025 (CHF13,508 Mil) to Mar. 2026 (CHF14,629 Mil).
Eli Lilly and Co's annual other long-term assets
increased
from Dec. 2023 (CHF9,052 Mil) to Dec. 2024 (CHF12,233 Mil) and
increased
from Dec. 2024 (CHF12,233 Mil) to Dec. 2025 (CHF13,508 Mil).
Eli Lilly and Co Other Long Term Assets Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Other Long Term Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.
What does a Other Long Term Assets of CHF14,629 Mil mean?
Eli Lilly and Co (XSWX:LLY) has a Other Long Term Assets of CHF14,629 Mil as of Mar. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Other Long Term Assets too high?
Eli Lilly and Co's current Other Long Term Assets is CHF14,629 Mil. Overall, Eli Lilly and Co has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Other Long Term Assets compare to JNJ and ABBV?
Eli Lilly and Co's Other Long Term Assets of CHF14,629 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Other Long Term Assets is CHF14,629 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,157.81, compared to a current price of CHF950.00 — trading 17.9% below its estimated fair value. The current Other Long Term Assets is CHF14,629 Mil. Eli Lilly and Co's overall GF Score™ is 99/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Other Long Term Assets is CHF14,629 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF950.00 is trading 17.9% below its estimated GF Value™ of CHF1,157.81.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Other Long Term Assets: CHF14,629 Mil
GF Value™: CHF1,157.81 vs. price of CHF950.00 (17.9% below fair value)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
99GF Score
Get the complete analysis for XSWX:LLY
Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
